Trzepatide consistently shows a greater percentage of weight loss compared to semaglutide in studies
GLP-1 RAs have shown a trend toward cardioprotective effects, including reductions in the risk of major cardiovascular eventssuch as stroke, MI, HF, peripheral artery disease, MACE, CVD, and cardiovascular mortality
Yasushi Honda, Takaomi Kessoku, Yoshio Sumida, Takashi Kobayashi, Takayuki Kato, Yuji Ogawa, Wataru Tomeno, Kento Imajo, Koji Fujita, Masato Yoneda, Koshi Kataoka, Masataka Taguri, Takeharu Yamanaka, Yuya Seko, Saiyu Tanaka, Satoru Saito, Masafumi Ono, Satoshi Oeda, Yuichiro Eguchi, Wataru Aoi, Kenji Sato, Yoshito Itoh, Atsushi Nakajima
Effects of Weight Loss on Lean Mass, Strength, Bone, and Aerobic Capacity
Settlement"
Key point: most evidence is still preclinical